Nature Reviews Gastroenterology &Hepatology最新文献_第10页

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment Μetabolic功能障碍相关的脂肪变性肝病：异质性代谢危险因素、机制和需要整体治疗的合并症

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-17 DOI: 10.1038/s41575-025-01045-z

Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi

{"title":"Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","authors":"Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi","doi":"10.1038/s41575-025-01045-z","DOIUrl":"10.1038/s41575-025-01045-z","url":null,"abstract":"Μetabolic dysfunction-associated steatotic liver disease (MASLD) comprises a heterogeneous condition in the presence of steatotic liver. There can be a hierarchy of metabolic risk factors contributing to the severity of metabolic dysfunction and, thereby, the associated risk of both liver and extrahepatic outcomes, but the precise ranking and combination of metabolic syndrome (MetS) traits that convey the highest risk of major adverse liver outcomes and extrahepatic disease complications remains uncertain. Insulin resistance, low-grade inflammation, atherogenic dyslipidaemia and hypertension are key to the mechanisms of liver and extrahepatic complications. The liver is pivotal in MetS progression as it regulates lipoprotein metabolism and secretes substances that affect insulin sensitivity and inflammation. MASLD affects the kidneys, heart and the vascular system, contributing to hypertension and oxidative stress. To address the global health burden of MASLD, intensified by obesity and type 2 diabetes mellitus epidemics, a holistic, multidisciplinary approach is essential. This approach should focus on both liver disease management and cardiometabolic risk factors. This Review examines the link between metabolic dysfunction and liver dysfunction and extrahepatic disease outcomes, the diverse mechanisms in MASLD due to metabolic dysfunction, and a comprehensive, personalized management model for patients with MASLD. This Review discusses the link between metabolic dysfunction-associated steatotic liver disease (MASLD) — a heterogeneous health condition — and hepatic and extrahepatic disease manifestations and provides a comprehensive platform for personalized, holistic management for patients with MASLD.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 5","pages":"314-328"},"PeriodicalIF":51.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroimmune interactions influence pancreatic glucagon secretion in fasting mice 神经免疫相互作用影响空腹小鼠胰高血糖素分泌

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-12 DOI: 10.1038/s41575-025-01049-9

Jordan Hindson

引用次数: 0

Author Correction: Understanding the therapeutic toolkit for inflammatory bowel disease 作者更正：了解炎症性肠病的治疗工具包

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-10 DOI: 10.1038/s41575-025-01047-x

Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese

引用次数: 0

Bridging the gap between science and survival 弥合科学与生存之间的鸿沟

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-07 DOI: 10.1038/s41575-025-01044-0

Ahsen Ustaoglu

引用次数: 0

New potent HBV replication inhibitors for the management of chronic hepatitis B are needed 需要新的有效的HBV复制抑制剂来治疗慢性乙型肝炎

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-05 DOI: 10.1038/s41575-025-01037-z

Timothy M. Block, Ju-Tao Guo, Fabien Zoulim, Charles M. Rice, Chloe L. Thio, William M. Schneider, Harvey J. Alter, Ira M. Jacobson, Robert G. Gish, Peter D. Block, Mark Sulkowski, Jordan J. Feld, Chari A. Cohen

引用次数: 0

MASLD as a non-communicable disease MASLD是非传染性疾病

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-04 DOI: 10.1038/s41575-025-01039-x

Silvia Sookoian, Carlos J. Pirola, Arun J. Sanyal

引用次数: 0

Is precision microbiome medicine just around the corner? 精密微生物组医学即将问世吗？

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-02-04 DOI: 10.1038/s41575-025-01040-4

Silvia Turroni

引用次数: 0

Understanding the therapeutic toolkit for inflammatory bowel disease 了解炎症性肠病的治疗方法

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-01-31 DOI: 10.1038/s41575-024-01035-7

Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese

{"title":"Understanding the therapeutic toolkit for inflammatory bowel disease","authors":"Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese","doi":"10.1038/s41575-024-01035-7","DOIUrl":"10.1038/s41575-024-01035-7","url":null,"abstract":"Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a group of chronic, immune-mediated disorders of the gastrointestinal tract that present substantial clinical challenges owing to their complex pathophysiology and tendency to relapse. A treat-to-target approach is recommended, involving iterative treatment adjustments to achieve clinical response, reduce inflammatory markers and achieve long-term goals such as mucosal healing. Lifelong medication is often necessary to manage the disease, maintain remission and prevent complications. The therapeutic landscape for IBD has evolved substantially; however, a ceiling on therapeutic efficacy remains and surgery is sometimes required (owing to uncontrolled disease activity or complications). Effective IBD management involves comprehensive care, including medication adherence and a collaborative clinician–patient relationship. This Review discusses current therapeutic options for IBD, detailing mechanisms of action, efficacy, safety profiles and guidelines for use of each drug class. We also explore emerging therapies and the role of surgery. Additionally, the importance of a multidisciplinary team and personalized care in managing IBD is emphasized, advocating for patient empowerment and involvement in treatment decisions. By synthesizing current knowledge and emerging trends, this Review aims to equip healthcare professionals with a thorough understanding of therapeutic options for IBD, enhancing informed, evidence-based decisions in clinical practice. The management of inflammatory bowel disease (IBD) continues to evolve. This Review is a practical guide on the therapeutic toolkit for IBD, with a focus on current and emerging IBD medications, how they relate to management strategies beyond drugs and the importance of the clinician–patient relationship.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 6","pages":"371-394"},"PeriodicalIF":51.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143071723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MASH-induced senescence and liver cancer mash诱导的衰老和肝癌

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-01-28 DOI: 10.1038/s41575-025-01043-1

Katrina Ray

引用次数: 0

Coeliac disease: complications and comorbidities 乳糜泻：并发症和合并症

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-01-28 DOI: 10.1038/s41575-024-01032-w

Jonas F. Ludvigsson, Jialu Yao , Benjamin Lebwohl, Peter H. R. Green, Shuai Yuan , Daniel A. Leffler

{"title":"Coeliac disease: complications and comorbidities","authors":"Jonas F. Ludvigsson, Jialu Yao \u0000 , Benjamin Lebwohl, Peter H. R. Green, Shuai Yuan \u0000 , Daniel A. Leffler","doi":"10.1038/s41575-024-01032-w","DOIUrl":"10.1038/s41575-024-01032-w","url":null,"abstract":"Coeliac disease is an autoimmune disease characterized by small intestinal villus atrophy and inflammation upon exposure to gluten. It has a global prevalence of approximately 1%. Although the gluten-free diet can be an effective treatment, this diet is burdensome with practical difficulties and frequent inadvertent gluten exposure. Moreover, there are a variety of potential complications and comorbidities of coeliac disease that might be related to malabsorption and/or chronic immune activation. Overall, individuals with coeliac disease have increased mortality compared with the general population, underscoring the severity of this common disease. Comorbidities and complications that have been associated with coeliac disease include poor growth, reproductive complications, kidney and liver diseases, respiratory disease (such as pneumonia) and infections (including sepsis). Furthermore, coeliac disease has been linked to other autoimmune disease and psychiatric disease, as well as certain cancers. Data suggest that mucosal healing on a gluten-free diet might protect against some, but not all, of these complications. In this Review, we present absolute and relative risks of coeliac-associated disorders. We discuss underlying mechanisms, the role of the gluten-free diet and mucosal healing, as well as implications for follow-up and non-dietary treatment of coeliac disease. In this Review, Ludvigsson and colleagues describe the epidemiological associations between coeliac disease and a variety of complications and comorbidities, and discuss the pathophysiology underlying these complications as well as implications for follow-up and treatment.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 4","pages":"252-264"},"PeriodicalIF":45.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0